Učitavanje...
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline
A recent analysis from the MPACT trial supported the use of carbohydrate antigen 19-9 (CA19-9) decrease as a predictive marker for survival in patients receiving nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer; however, CA19-9 cannot be used in this capacity for...
Spremljeno u:
| Izdano u: | Ann Oncol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959922/ https://ncbi.nlm.nih.gov/pubmed/27240995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw177 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|